Exploring how treatment adherence affects tuberculosis outcomes
Understanding the mediating role of adherence in risk factors for unfavorable outcomes from tuberculosis treatment
This study is looking at how sticking to treatment affects the recovery of people with tough forms of tuberculosis, like rifampicin- and multidrug-resistant TB, and it aims to find out how other health issues might make it harder to follow the treatment plan so we can help patients do better.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11004078 on NIH RePORTER |
What this research studies
This research investigates the role of treatment adherence in influencing the outcomes of patients with rifampicin- and multidrug-resistant tuberculosis (TB). It aims to identify how various risk factors, such as co-infections or health conditions, impact treatment success through adherence. By analyzing the causal relationships between these factors and treatment outcomes, the study seeks to develop targeted interventions that can improve adherence and, consequently, treatment results for patients. The approach combines advanced statistical methods to ensure that the findings are actionable and relevant for patient care.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with rifampicin- or multidrug-resistant tuberculosis who may face challenges in adhering to their treatment regimen.
Not a fit: Patients with non-resistant forms of tuberculosis or those who are not currently undergoing treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that enhance adherence and overall outcomes for patients with tuberculosis.
How similar studies have performed: Previous research has shown that addressing adherence can significantly improve treatment outcomes in various chronic diseases, suggesting a promising avenue for tuberculosis treatment as well.
Where this research is happening
Boston, United States
- Harvard Medical School — Boston, United States (Active)
Researchers
- Principal investigator: Franke, Molly Forrest — Harvard Medical School
- Study coordinator: Franke, Molly Forrest
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.